Technology Commercialization Office

Showing 9 result(s) for "Oncology"



Three-way junction nanoparticles for delivery of tamoxifen and other therapeutics directly to tumor cells.

Novel strategy to improve efficiency and specificity of tumor treatment via combinative use of a split & splice protein toxin and oncolytic virus.

A novel therapeutic strategy to sensitize Hepatocellular Carcinoma tumors to a multikinase inhibitor for advanced stage treatment.

A combination-therapy that has the potential to overcome and/or prevent the commonly observed acquisition of sorafenib resistance, which is associated with treatment failure in patients with hepatocellular carcinoma.

An efficient delivery vehicle for therapeutic oligonucleotides with high efficiency.

Self-assembling, highly stable RNA cages amenable to custom functionalization and cargo delivery

Parthenolide analogues derived from plants could be effective in treating leukemia or supplementing other treatments.

An improved delivery mechanism has been developed for hydrophobic drugs such as camptothecin which will increase chemotherapeutic efficacy.

Nucleolin (NCL) is up-regulated in cancer cells, and modulates pro-tumorigenic pathways and chemoresistance. This anti-NCL agent binds and blocks NCL signaling, and may be optimized as cancer therapeutic and diagnostic tool.